期刊文献+

检测p53基因诊断犬乳腺恶性肿瘤的初步研究 被引量:1

原文传递
导出
摘要 研究犬乳腺恶性肿瘤p53基因在体内的表达,探讨其与犬乳腺肿瘤恶性程度的相关性。根据GenBank中犬p53基因序列以及文献报道的高度保守区域,设计1对引物,同时以GAPDH基因序列作为内参,将临床采集的犬乳腺肿瘤组织进行p53基因PCR检测,分析p53基因的表达量变化趋势。结果表明,良性肿瘤组织p53基因的表达量极小;恶性肿瘤组织中的表达量随着其恶化程度明显增高。由此可推断,检测p53基因的表达量可作为诊断犬乳腺肿瘤、判断肿瘤恶化程度及预后的一个重要指标。
出处 《畜牧与兽医》 北大核心 2012年第4期77-79,共3页 Animal Husbandry & Veterinary Medicine
基金 上海农林职业技术学院科研项目(090603)
  • 相关文献

参考文献8

  • 1Gottlied T M,Oren M. P53 in growth control and neoglasia[J].Biochem Bio phys Acta,1996.77.
  • 2Vousden K H,Lane D P. p53 in health and disease[J].Nat Rev Mol Cell Bicol,2007,(4):275-283.doi:10.1038/nrm2147.
  • 3Vousden K H,Prives C. Blinded by the light:the growing complexity of p53[J].Cell,2009,(03):413-431.doi:10.1016/j.cell.2009.04.037.
  • 4傅西林.乳腺肿瘤病理诊断图谱[M]北京:科学技术文献出版社,200331.
  • 5Helal E,Khalifa A,Kamel A S. Immunohisto-chemical expression of p53 and cerbB2 protein in breast cancer in Egypt[J].Anticancer Research,2000,(3B):2145-2150.
  • 6王坤,周清,郑登云,廖宁,李学瑞.p53、bcl-2和CD44v6蛋白表达与乳腺癌转移的相关性研究[J].肿瘤防治研究,2005,32(12):748-751. 被引量:5
  • 7Poelman S M,Heimann R,Fleming G F. lnvariant p53 immunostaining in primary and recurrent breast cancer[J].European Journal of Cancer,2004,(01):2-32.
  • 8Sangrajrang S,Arpornwirat W,Cheirsilpa A. Serum p53 antibodies in correlation to other biological parameters of breast cancer[J].Cancer Detection and Prevention,2003,(03):182-186.

二级参考文献12

  • 1Elston CW, Ellis IO. Pathological prognostic factors in breast cancer[J]. Histopathology, 1991, 19 (5) :403-410.
  • 2Sabsttini E, Bisgaard K, Ascani S, et al. The EnVision + + system: a new immunohistochemical method for diagnostics and research. Critrical comparison with the APAAP, ChemMate, CSA, LSAN2, and SABC techniques [J]. J Clin Pathol, 1998,51(7) :506-511.
  • 3Valerie R, David K, Ennapadam V, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer [J].Cancer Res, 1995,55(21 ) :5038-5042.
  • 4Gee JMW, Robertson JFR, Ellis IO, et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy[J]. Int J Cancer, 1994,59(5) :619-628.
  • 5步宏 庞宗国.c—erbB—2基因在乳腺癌中的研究进展[J].基因快讯,2001,1:12-14.
  • 6Norberg T, Klaar S, Karl G, et al. Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort[J]. Cancer Res, 2001,61 (22) :8317-8321.
  • 7OdaE, OhkiR, Murasawa H, et al. Noxa, a BH3 only member of the Bcl-2 family and candidate mediator of p53 - induced apoptosis[J]. Science,2000, 288 (5468):1053-1058.
  • 8Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node- positive breast cancer[J]. J Clin Oncol, 2000,18(20):3471-3479.
  • 9Paik S, Bryant J, Tan-Chiu E, et al. HER-2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15[J]. J Natl Cancer Inst, 2000,92(24) : 1991-1998.
  • 10戴备军,赵仲生.CD44V6在非小细胞肺癌中的表达及其预后意义[J].实用肿瘤杂志,1998,13(4):214-216. 被引量:20

共引文献4

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部